PRINCETON, NJ and REHOVOT, ISRAEL, United States, via eTeligis Inc., 06/26/2014 - - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/390,995, entitled "Compositions and Methods for Prognosis and Treatment of Prostate Cancer." The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.
Prostate cancer typically is first suspected by elevated levels of serum Prostate Specific Antigen (PSA). However, PSA levels are often elevated for reasons unrelated to prostate cancer. Although an elevated PSA level often leads to biopsy, about 80% of all prostate biopsies are either negative or indicate a low likelihood of high-grade cancer. Further complicating prostate cancer diagnosis and treatment is the difficulty in determining which cancers are low-risk and which are high-risk.
"The biomarker we have identified could be used for predicting the aggressiveness of prostate tumors and for determining the most appropriate course of treatment," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. "In addition, this biomarker, over-expressed in primary prostate tumors could be used as a therapeutic target for prostate cancer. Rosetta Genomics continues to fortify its intellectual property portfolio to protect and broaden our leading position in microRNA technology. We look forward to monetizing this new piece of intellectual property."
Rosetta's robust patent portfolio includes 35 issued patents, including 31 in the U.S. In addition, Rosetta has 47 patent applications pending, of which 25 are in the U.S.
About Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in males, with 1 of every 7 men being diagnosed during his lifetime, and is the second most common cause of cancer-related death in men in the United States. The American Cancer Society estimates that in 2014 about 233,000 new cases of prostate cancer will be diagnosed and about 29,480 men will die of prostate cancer.
About Rosetta Genomics
Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics. Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. For more information please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, Rosetta's Cancer of Origin Test™, Rosetta's development or commercialization of molecular diagnostics, prognostic or therapeutic services or tool, the timeline for the development of Rosetta's potential molecular diagnostic or prognostic assays or therapeutics, and specifically its development of a diagnostic or prognostic assays or therapeutics,, the market acceptance of Rosetta's cancer testing services, particularly the Rosetta Cancer Origin Test™, Rosetta monetizing its intellectual property in any way and Rosetta's development of personalized medicine products and services, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.
Rosetta Genomics Contact:
Rosetta Genomics
Ken Berlin
President & CEO
609-419-9003
Investor Contacts:
LHA
Anne Marie Fields
212-838-3777
or
Bruce Voss
310-691-7100
SOURCE: Rosetta Genomics, Ltd.
Associated Documentation:
Link to submission on http://www.eteligis.com
ROSG_6-26-2014_LST_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment